The development of proteasome inhibitors as anticancer drugs.
摘要：
The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins. Because these pathways are critical for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy. Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clinical trials. Efficacy and safety results from a phase 2 clinical trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy.
展开
DOI：
10.1016/S1535-6108(04)00120-5
被引量：
年份：
2004
Elsevier
Elsevier
(全网免费下载)
BMJ
国家科技图书文献中心
(权威机构)
Semantic Scholar
查看更多
掌桥科研
万方医学
dx.doi.org
Cell Press
NCBI
Cell Press
(全网免费下载)
Europe PMC
Oxford Univ Press
NCBI
ResearchGate
EBSCO
en.zl50.com
bvsalud.org
mct.aacrjournals.org
学术范
mendeley.com
jpet.aspetjournals.org
seminoncol.org
ar.iiarjournals.org
onAcademic
embor.embopress.org
cghjournal.org
pubfacts.com
molbiolcell.org
ajplung.physiology.org
readcube.com
deepdyve.com
www.socolar.com
学术范
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
